

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Title of paper:	Aflibercept dose intensification		
Meeting date:	Wednesday 6 th July 2022		
Agenda item:	To be completed by APC secretary	To be completed by APC secretary	To be completed by APC secretary
Author and contributors:	<ul style="list-style-type: none"> Carina Joanes (Lead Commissioning Pharmacist, Guildford & Waverley Place) Clare Johns (Lead Commissioning Pharmacy Technician, Surrey Heartlands CCG) 		
Paper type	Briefing		
For:	For approval		
<p>Executive Summary: <i>(provide a short description of the subject matter and draw attention to the issues / facts and the proposal)</i></p> <p>The Area Prescribing Committee will be asked to:</p> <ul style="list-style-type: none"> DO NOT SUPPORT dose intensification of aflibercept, as per change in license since NICE guidance was published <p><u>Aflibercept dose intensification</u></p> <p>When NICE was published in 2013 for Aflibercept (TA294 -July 2013), the licensed dose was as follows:</p> <ul style="list-style-type: none"> the recommended dose for aflibercept is 2 mg and that treatment should be given monthly for 3 consecutive doses, followed by 1 injection every 2 months. <p>In May 2021, the license for aflibercept was updated as follows for wet AMD</p> <p>www.medicines.org.uk</p> <p><i>The recommended dose for Eylea is 2 mg aflibercept, equivalent to 50 microlitres.</i></p> <p><i>Eylea treatment is initiated with one injection per month for three consecutive doses. The treatment interval is then extended to two months.</i></p> <p><i>Based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at two months or further extended using a treat-and-extend dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly.</i></p> <p><i>There is no requirement for monitoring between injections. Based on the physician’s judgement the schedule of monitoring visits may be more frequent than the injection visits.</i></p> <p>Treatment intervals greater than four months or shorter than 4 weeks between injections have not been studied.</p>			

This review of the licence has not been considered by NICE or the APC and monthly ranibizumab is routinely funded when more frequent injections are required.

Summary: *(What is the APC being asked to do and why)*

The Area Prescribing Committee will be asked to:

- **DO NOT SUPPORT** dose intensification of aflibercept, as per change in license since NICE guidance was published